Calcium electroporation as an adjunct therapy for pembrolizumab-resistant bladder cancer: a case report

References

• Falk H, Matthiessen LW, Wooler G, et al. Calcium electroporation for treatment of cutaneous metastases; a randomized double-blinded phase II study, comparing the effect of calcium electroporation with electrochemotherapy. Acta Oncol. 2018;57(3):311–319. doi: 10.1080/0284186X.2017.1355109.
   PubMed Web of Science ®Google Scholar
• Plaschke CC, Gehl J, Johannesen HH, et al. Calcium electroporation for recurrent head and neck cancer: a clinical phase I study. Laryngoscope Investig Otolaryngol. 2019;4(1):49–56. doi: 10.1002/lio2.233.
   PubMed Web of Science ®Google Scholar
• Agoston D, Baltas E, Ocsai H, et al. Evaluation of calcium electroporation for the treatment of cutaneous metastases: a double blinded randomised controlled phase II trial. Cancers. 2020;12(1):179. doi: 10.3390/cancers12010179.
   PubMed Web of Science ®Google Scholar
• Frandsen SK, Gissel H, Hojman P, et al. Direct therapeutic applications of calcium electroporation to effectively induce tumor necrosis. Cancer Res. 2012;72(6):1336–1341. doi: 10.1158/0008-5472.CAN-11-3782.
   PubMed Web of Science ®Google Scholar
• Hansen EL, Sozer EB, Romeo S, et al. Dose-dependent ATP depletion and cancer cell death following calcium electroporation, relative effect of calcium concentration and electric field strength. PLoS One. 2015;10(4):e0122973. doi: 10.1371/journal.pone.0122973.
   PubMed Web of Science ®Google Scholar
• Stranzenbach R, Doerler M, Scholl L, et al. Calcium electroporation in primary cutaneous marginal zone lymphoma. J Dtsch Dermatol Ges. 2021;19(10):1510–1512. doi: 10.1111/ddg.14583.
   Web of Science ®Google Scholar
• Falk H, Forde PF, Bay ML, et al. Calcium electroporation induces tumor eradication, long-lasting immunity and cytokine responses in the CT26 Colon cancer mouse model. Oncoimmunology. 2017;6(5):e1301332. doi: 10.1080/2162402X.2017.1301332.
   PubMed Web of Science ®Google Scholar
• Frandsen SK, Gehl J, Tramm T, et al. Calcium electroporation of equine sarcoids. Animals. 2020;10(3):517. doi: 10.3390/ani10030517.
   Web of Science ®Google Scholar
• Szewczyk A, Gehl J, Daczewska M, et al. Calcium electroporation for treatment of sarcoma in preclinical studies. Oncotarget. 2018;9(14):11604–11618. doi: 10.18632/oncotarget.24352.
   PubMedGoogle Scholar
• Pakhomova ON, Gregory B, Semenov I, et al. Calcium-mediated pore expansion and cell death following nanoelectroporation. Biochim Biophys Acta. 2014;1838(10):2547–2554. doi: 10.1016/j.bbamem.2014.06.015.
   PubMed Web of Science ®Google Scholar
• Gerlini G, Di Gennaro P, Borgognoni L. Enhancing anti-melanoma immunity by electrochemotherapy and in vivo dendritic-cell activation. Oncoimmunology. 2012;1(9):1655–1657. doi: 10.4161/onci.21991.
   PubMed Web of Science ®Google Scholar
• Falk H, Lambaa S, Johannesen HH, et al. Electrochemotherapy and calcium electroporation inducing a systemic immune response with local and distant remission of tumors in a patient with malignant melanoma – a case report. Acta Oncol. 2017;56(8):1126–1131. doi: 10.1080/0284186X.2017.1290274.
   PubMed Web of Science ®Google Scholar
• Wu M, Huang Q, Xie Y, et al. Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation. J Hematol Oncol. 2022;15(1):24. doi: 10.1186/s13045-022-01242-2.
   PubMed Web of Science ®Google Scholar
• Hegde PS, Karanikas V, Evers S. The where, the when, and the how of immune monitoring for cancer immunotherapies in the era of checkpoint inhibition. Clin Cancer Res. 2016;22(8):1865–1874. doi: 10.1158/1078-0432.CCR-15-1507.
   PubMed Web of Science ®Google Scholar
• Teng MW, Ngiow SF, Ribas A, et al. Classifying cancers based on T-cell infiltration and PD-L1. Cancer Res. 2015;75(11):2139–2145. doi: 10.1158/0008-5472.CAN-15-0255.
   PubMed Web of Science ®Google Scholar
• Bonaventura P, Shekarian T, Alcazer V, et al. Cold tumors: a therapeutic challenge for immunotherapy. Front Immunol. 2019;10:168. doi: 10.3389/fimmu.2019.00168.
   PubMed Web of Science ®Google Scholar
• Resch I, Shariat SF, Gust KM. PD-1 and PD-L1 inhibitors after platinum-based chemotherapy or in first-line therapy in cisplatin-ineligible patients: dramatic improvement of prognosis and overall survival after decades of hopelessness in patients with metastatic urothelial cancer. Memo. 2018;11(1):43–46. doi: 10.1007/s12254-018-0396-y.
   PubMedGoogle Scholar
• Coulie PG, Van den Eynde BJ, van der Bruggen P, et al. Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy. Nat Rev Cancer. 2014;14(2):135–146. doi: 10.1038/nrc3670.
   PubMed Web of Science ®Google Scholar
• Jensen KB, Lonkvist CK, Gehl J, et al. Calcium electroporation for management of cutaneous metastases in HER2-Positive breast cancer: a case report. Case Rep Dermatol. 2022;14(3):330–338. doi: 10.1159/000526157.
   PubMed Web of Science ®Google Scholar
• Vissing M, Ploen J, Pervan M, et al. Study protocol designed to investigate tumour response to calcium electroporation in cancers affecting the skin: a non-randomised phase II clinical trial. BMJ Open. 2021;11(6):e046779. doi: 10.1136/bmjopen-2020-046779.
   PubMed Web of Science ®Google Scholar
• Bastrup FA, Vissing M, Gehl J. Electrochemotherapy for metastatic cutaneous melanoma. Acta Oncol. 2022;61(5):531–532. doi: 10.1080/0284186X.2022.2057199.
   PubMed Web of Science ®Google Scholar
• Falk H, Vissing M, Wooler G, et al. Calcium electroporation for keloids: a first-in-Man phase I study. Dermatology. 2021;237(6):961–969. doi: 10.1159/000514307.
   PubMed Web of Science ®Google Scholar
• Vestergaard K, Vissing M, Gehl J, et al. Qualitative investigation of experience and quality of life in patients treated with calcium electroporation for cutaneous metastases. Cancers. 2023;15(3):599. doi: 10.3390/cancers15030599.
   PubMed Web of Science ®Google Scholar
• Vissing M, Pervan M, Pløen J, et al. Calcium electroporation in cutaneous metastases – A non-randomised phase II multicentre clinical trial. European Journal of Surgical Oncology. 2023; doi: 10.1016/j.ejso.2023.04.024.
   PubMed Web of Science ®Google Scholar
• Stewart TJ, Abrams SI. How tumours escape mass destruction. Oncogene. 2008;27(45):5894–5903. doi: 10.1038/onc.2008.268.
   PubMed Web of Science ®Google Scholar
• Gooden MJ, de Bock GH, Leffers N, et al. The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis. Br J Cancer. 2011;105(1):93–103. doi: 10.1038/bjc.2011.189.
   PubMed Web of Science ®Google Scholar
• Wahid M, Akhter N, Jawed A, et al. Pembrolizumab’s non-cross resistance mechanism of action successfully overthrown ipilimumab. Crit Rev Oncol Hematol. 2017;111:1–6. doi: 10.1016/j.critrevonc.2017.01.001.
   PubMed Web of Science ®Google Scholar
• Fuks Z, Strober S, Bobrove AM, et al. Long term effects of radiation of T and B lymphocytes in peripheral blood of patients with Hodgkin’s disease. J Clin Invest. 1976;58(4):803–814. doi: 10.1172/JCI108532.
   PubMed Web of Science ®Google Scholar
• Stewart CC, Perez CA. Effect of irradiation on immune responses. Radiology. 1976;118(1):201–210. doi: 10.1148/118.1.201.
   PubMed Web of Science ®Google Scholar
• Theelen W, Chen D, Verma V, et al. Pembrolizumab with or without radiotherapy for metastatic non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Respir Med. 2021;9(5):467–475. doi: 10.1016/S2213-2600(20)30391-X.
   PubMed Web of Science ®Google Scholar
• Ho AY, Barker CA, Arnold BB, et al. A phase 2 clinical trial assessing the efficacy and safety of pembrolizumab and radiotherapy in patients with metastatic triple-negative breast cancer. Cancer. 2020;126(4):850–860. doi: 10.1002/cncr.32599.
   PubMed Web of Science ®Google Scholar
• Dudda JC, Martin SF. Tissue targeting of T cells by DCs and microenvironments. Trends Immunol. 2004;25(8):417–421. doi: 10.1016/j.it.2004.05.008.
   PubMed Web of Science ®Google Scholar
• Van Damme P, Van Herck K. A review of the long-term protection after hepatitis A and B vaccination. Travel Med Infect Dis. 2007;5(2):79–84. doi: 10.1016/j.tmaid.2006.04.004.
   PubMedGoogle Scholar